Whether improvements in the delivery of training in biopharmaceutical manufacturing are needed is an open question, and the answers are not clear-cut. BioPlan recently conducted independent research to address this question.
Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
Pharma and biotech companies have invested heavily in externalized research, development, and manufacturing in recent years – but their methods of sharing critical data are still rarely fit for purpose.
Brady Haggstrom, IDBS, looks at the changing landscape of drug development and delivery, which is more and more outsourced nowadays, and how technology can help protect sensitive research data.
Fast and efficient process development and scale-up contributes to a shortened time to market. This application note demonstrates a multidimensional scale-up (change of both column diameter and bed height) of a mAb capture step, using the ÄKTA pilot 600 chromatography system.
Calculation examples that highlight scenarios where the enhanced capacity and alkaline‑stability of MabSelect PrismA can provide process economic benefits to large‑scale mAb processing.
The availability of commercial multiplex cytokine assays enables end users to interrogate an entire network of cytokines in a single sample.
Just as good things come in small packages, small vesicles promise big biological impact
Multiplex digital PCR enables tracking of treatment efficacy using liquid biopsies.
How digital PCR technology is helping scientists in their quest to break through the current limits of nucleic acid detection and quantification.
|
|
|
|
|
|
|
|
|